Illimis Therapeutics
PrivateLast Round
Grant
Jul 15, 2025
Est. Valuation
$107.17M
Total Funding Raised
$60.01M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Illimis Therapeutics is a biotechnology company developing fusion protein-based therapeutics for the treatment of intractable diseases like Alzheimer's and other immune-related disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Illimis Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Illimis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jul 15, 2025 | ||||
| Series B | Jul 14, 2025 | ||||
| Series A | Apr 14, 2023 | ||||
| Seed | Dec 1, 2021 |
Key People
Founding team and executive leadership
Illimis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hana Ventures | Series B |
| DSC Investment | Series B |
| A Ventures | Series B |
| Shinhan Venture Investment | Series B |
| DAYLI Partners | VC Round, Series B, Series A |
| TS Investment | Series B |
| GS Ventures | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 20, 2026
Monthly visitors increased 137% MoM.
- Jul 15, 2025
$1.6M grant awarded
Illimis Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Illimis Therapeutics's valuation, stock price, and market status.